Skip to content

Study · Randomized controlled trial · n = 34 · 2018

12 results

Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients.

Tonneijck L, Muskiet MHA, Twisk JW, Kramer MHH, Danser AHJ, Joles JA, Smits MM, van Raalte DH

Hypertension (Dallas, Tex. : 1979)18 Jun 2018Cited by 12 (Europe PMC)

PMID29915021 (opens in a new tab)DOI10.1161/hypertensionaha.117.10740 (opens in a new tab)PepBankPUB-29915021
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In insulin-glargine-treated patients with type 2 diabetes, lixisenatide did not affect fasting systemic hemodynamics versus insulin glulisine.

    In plain wordsLixisenatide did not change fasting circulation measurements compared with insulin glulisine in patients with type 2 diabetes.

    Peptide
    Lixisenatide
    Outcome
    No significant changeFasting systemic hemodynamics
    Study

    n = 34

    Comparator
    Insulin glulisine
    Analysis
    Secondary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    20 μg once daily · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Lixisenatide did not affect fasting systemic hemodynamics compared with insulin glulisine from baseline to week 8.
    1 context sentence
    Summary · context
    that were randomized to once-daily lixisenatide 20 μg or once-daily titrated insulin glulisine for 8 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, overall postbreakfast systolic blood pressure tended to increase by 5.2 mm Hg with lixisenatide versus insulin glulisine (P = 0.087).

    In plain wordsAfter breakfast, upper blood pressure tended to be higher with lixisenatide than with insulin glulisine.

    Peptide
    Lixisenatide
    Outcome
    IncreaseOverall postbreakfast systolic blood pressure
    Study

    n = 34

    Comparator
    Insulin glulisine
    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    20 μg once daily · 8 weeksAs given in this study (human).

    Measurements

    Systolic BP difference
    5.2 mm Hg
    overall postbreakfast
    SD or error
    2.9 mm Hg
    reported ±
    P value
    0.087
    overall systolic BP

    Source sentences

    Summary
    Postbreakfast overall, lixisenatide compared with insulin glulisine tended to increase systolic BP by 5.2±2.9 mm Hg (P=0.087)
    1 context sentence
    Summary · context
    that were randomized to once-daily lixisenatide 20 μg or once-daily titrated insulin glulisine for 8 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, lixisenatide increased overall postbreakfast diastolic pressure versus insulin glulisine.

    In plain wordsAfter breakfast, lower blood pressure was higher with lixisenatide than insulin glulisine.

    Peptide
    Lixisenatide
    Outcome
    IncreaseOverall postbreakfast diastolic blood pressure
    Study

    n = 34

    Comparator
    Insulin glulisine
    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    20 μg once daily · 8 weeksAs given in this study (human).

    Measurements

    Diastolic BP difference
    5.4 mm Hg
    overall postbreakfast
    SD or error
    1.4 mm Hg
    reported ±
    P value
    < 0.001
    diastolic BP

    Source sentences

    Summary
    Postbreakfast overall, lixisenatide compared with insulin glulisine tended to increase systolic BP by 5.2±2.9 mm Hg (P=0.087) and increased diastolic BP by 5.4±1.4 mm Hg (PP=0.007) and +7.2±1.5 mm Hg (P<0.001).
    1 context sentence
    Summary · context
    that were randomized to once-daily lixisenatide 20 μg or once-daily titrated insulin glulisine for 8 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, the maximal postbreakfast systolic blood pressure difference was higher with lixisenatide than with insulin glulisine (+10.2 mm Hg, P = 0.007).

    In plain wordsThe largest upper blood pressure difference after breakfast was higher with lixisenatide than with insulin glulisine.

    Peptide
    Lixisenatide
    Outcome
    IncreaseMaximal postbreakfast systolic blood pressure difference
    Study

    n = 34

    Comparator
    Insulin glulisine
    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    20 μg once daily · 8 weeksAs given in this study (human).

    Measurements

    Maximal systolic BP difference
    10.2 mm Hg
    lixisenatide versus insulin glulisine
    SD or error
    3.7 mm Hg
    reported ±
    P value
    0.007
    maximal systolic BP

    Source sentences

    Summary
    Postbreakfast overall, lixisenatide compared with insulin glulisine tended to increase systolic BP by 5.2±2.9 mm Hg (P=0.087) and increased diastolic BP by 5.4±1.4 mm Hg (PP=0.007) and +7.2±1.5 mm Hg (P<0.001).
    1 context sentence
    Summary · context
    that were randomized to once-daily lixisenatide 20 μg or once-daily titrated insulin glulisine for 8 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, the maximal postbreakfast diastolic blood pressure difference was higher with lixisenatide than with insulin glulisine (+7.2 mm Hg, P < 0.001).

    In plain wordsThe largest lower blood pressure difference after breakfast was higher with lixisenatide than with insulin glulisine.

    Peptide
    Lixisenatide
    Outcome
    IncreaseMaximal postbreakfast diastolic blood pressure difference
    Study

    n = 34

    Comparator
    Insulin glulisine
    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    20 μg once daily · 8 weeksAs given in this study (human).

    Measurements

    Maximal diastolic BP difference
    7.2 mm Hg
    lixisenatide versus insulin glulisine
    SD or error
    1.5 mm Hg
    reported ±
    P value
    < 0.001
    maximal diastolic BP

    Source sentences

    Summary
    Postbreakfast overall, lixisenatide compared with insulin glulisine tended to increase systolic BP by 5.2±2.9 mm Hg (P=0.087) and increased diastolic BP by 5.4±1.4 mm Hg (PP=0.007) and +7.2±1.5 mm Hg (P<0.001).
    1 context sentence
    Summary · context
    that were randomized to once-daily lixisenatide 20 μg or once-daily titrated insulin glulisine for 8 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, lixisenatide increased systemic vascular resistance versus insulin glulisine.

    In plain wordsLixisenatide increased resistance to blood flow compared with insulin glulisine in patients with type 2 diabetes.

    Peptide
    Lixisenatide
    Outcome
    IncreaseSystemic vascular resistance
    Study

    n = 34

    Comparator
    Insulin glulisine
    Analysis
    Secondary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    20 μg once daily · 8 weeksAs given in this study (human).

    Measurements

    P value
    < 0.001
    systemic vascular resistance

    Source sentences

    Summary
    Lixisenatide increased systemic vascular resistance (PP=0.007).
    1 context sentence
    Summary · context
    that were randomized to once-daily lixisenatide 20 μg or once-daily titrated insulin glulisine for 8 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, lixisenatide increased arterial stiffness versus insulin glulisine.

    In plain wordsLixisenatide increased artery stiffness compared with insulin glulisine in patients with type 2 diabetes.

    Peptide
    Lixisenatide
    Outcome
    IncreaseArterial stiffness
    Study

    n = 34

    Comparator
    Insulin glulisine
    Analysis
    Secondary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    20 μg once daily · 8 weeksAs given in this study (human).

    Measurements

    P value
    0.007
    arterial stiffness

    Source sentences

    Summary
    Lixisenatide increased systemic vascular resistance (PP=0.007).
    1 context sentence
    Summary · context
    that were randomized to once-daily lixisenatide 20 μg or once-daily titrated insulin glulisine for 8 weeks.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, lixisenatide and insulin glulisine showed no between-group differences in overall postbreakfast heart rate, cardiac output or cardiac sympathovagal balance, or in circulating catecholamines, angiotensin II or aldosterone.

    In plain wordsOverall after breakfast, heart rate, cardiac output and cardiac nerve balance did not differ with lixisenatide versus insulin glulisine, and neither did circulating hormone levels.

    Peptide
    Lixisenatide
    Outcome
    No significant changeOverall postbreakfast heart rate and related hemodynamic and hormonal measures
    Study

    n = 34

    Comparator
    Insulin glulisine
    Analysis
    Secondary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    20 μg once daily · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    No between-group differences in overall postbreakfast heart rate, cardiac output, or cardiac sympathovagal balance, and circulating catecholamines, angiotensin II, or aldosterone were observed.
    1 context sentence
    Summary · context
    that were randomized to once-daily lixisenatide 20 μg or once-daily titrated insulin glulisine for 8 weeks.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, lixisenatide and insulin glulisine lowered HbA1c similarly.

    In plain wordsLixisenatide and insulin glulisine reduced long-term blood sugar similarly in patients with type 2 diabetes.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedHbA1c reduction
    Study

    n = 34

    Comparator
    Insulin glulisine
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 μg once daily · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Both treatments lowered HbA1c similarly, whereas lixisenatide achieved greater reductions in postbreakfast plasma glucose excursions.
    1 context sentence
    Summary · context
    that were randomized to once-daily lixisenatide 20 μg or once-daily titrated insulin glulisine for 8 weeks.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, lixisenatide reduced postbreakfast glucose excursions more than insulin glulisine.

    In plain wordsLixisenatide reduced blood sugar rises after breakfast more than insulin glulisine in patients with type 2 diabetes.

    Peptide
    Lixisenatide
    Outcome
    DecreasePostbreakfast plasma glucose excursions
    Study

    n = 34

    Comparator
    Insulin glulisine
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 μg once daily · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Both treatments lowered HbA1c similarly, whereas lixisenatide achieved greater reductions in postbreakfast plasma glucose excursions.
    1 context sentence
    Summary · context
    that were randomized to once-daily lixisenatide 20 μg or once-daily titrated insulin glulisine for 8 weeks.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, lixisenatide slowed gastric emptying in the comparison with insulin glulisine.

    In plain wordsLixisenatide slowed stomach emptying in the study comparing it with insulin glulisine.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGastric emptying rate
    Study

    n = 34

    Comparator
    Insulin glulisine
    Analysis
    Secondary
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    20 μg once daily · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Lixisenatide slowed gastric emptying rate, which statistically explained changes in postbreakfast BP.
    1 context sentence
    Summary · context
    that were randomized to once-daily lixisenatide 20 μg or once-daily titrated insulin glulisine for 8 weeks.
  12. 12HumanObservational studyMechanism

    In patients with type 2 diabetes receiving lixisenatide, slower gastric emptying statistically explained postbreakfast blood pressure changes.

    In plain wordsIn patients receiving lixisenatide, slower stomach emptying statistically explained blood pressure changes after breakfast.

    Peptide
    Lixisenatide
    Outcome
    Not applicableStatistical explanation of postbreakfast blood pressure changes
    Study

    n = 34

    Analysis
    Secondary
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    20 μg once daily · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Lixisenatide slowed gastric emptying rate, which statistically explained changes in postbreakfast BP.
    1 context sentence
    Summary · context
    that were randomized to once-daily lixisenatide 20 μg or once-daily titrated insulin glulisine for 8 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.